CMDBioscienceSM Raises $1M in Series A Funding

CMDBioscienceSM Inc., a New Haven, CT-based computational biotechnology company that specializes in the computer-enabled analysis, modeling and design of therapeutic protein-peptide interactions, raised $1m in Series A funding.

Backers include existing investor Connecticut Innovations, which injected $500k in CMD, LaunchCapital, Enhanced Capital Connecticut, the Mohegan Tribe, and an individual investor.

Led by Joseph Audie, Ph.D., CEO, CMDBioscienceSM provides a proprietary validated discovery platform CMDInventusSM that allows partner organizations to identify novel peptide hits, understand the structural basis of protein-peptide interactions, and rationally optimize peptide leads.
The company is a tenant in the CI-managed technology business incubator [email protected] Park at Yale.

In conjunction with the funding, CI managing director of investments Daniel Wagner joined CMD’s board of directors.



Join the discussion